CHADI CALARGE to Antipsychotic Agents
This is a "connection" page, showing publications CHADI CALARGE has written about Antipsychotic Agents.
Connection Strength
5.050
-
Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023 11; 62(11):1245-1255.
Score: 0.661
-
CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915.
Score: 0.443
-
Iron homeostasis during risperidone treatment in children and adolescents. J Clin Psychiatry. 2015 Nov; 76(11):1500-5.
Score: 0.391
-
Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013 Mar; 23(2):101-9.
Score: 0.326
-
Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr. 2012 Dec; 161(6):1010-5.
Score: 0.310
-
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9.
Score: 0.285
-
Iron status in toddlerhood predicts sensitivity to psychostimulants in children. J Atten Disord. 2012 May; 16(4):295-303.
Score: 0.276
-
A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47.
Score: 0.264
-
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec; 19(6):320-7.
Score: 0.260
-
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009 Apr; 19(2):101-9.
Score: 0.248
-
Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
Score: 0.180
-
The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
Score: 0.172
-
Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
Score: 0.169
-
Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
Score: 0.168
-
Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
Score: 0.167
-
Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251.
Score: 0.118
-
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
Score: 0.112
-
Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755.
Score: 0.109
-
Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 06; 5:e652.
Score: 0.097
-
Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013 May; 23(4):282-9.
Score: 0.082
-
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90.
Score: 0.075
-
An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry. 2011 Nov; 23(4):270-6.
Score: 0.074
-
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May; 19(5):373-82.
Score: 0.062